Hospital
Amery Regional Medical Center, INC
Amery Regional Medical Center, INC was paid $8.59M by Medicaid between Jan 2018 and Dec 2024, across 162 billing codes. Its largest line is 99283, emergency room visit (moderate) — 13% of everything it billed.
33Billing provider infoAMERY REGIONAL MEDICAL CENTER, INC
AMERY, WI 54001
AMERY, WI 54001
33aNPI1093763518assigned 05/05/2006
33bProvider typeCritical Access Hospital
28Total paid$8.59M
24GClaims223,649
24DCodes billed162
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#14 of 48
Median peer was paid$4.30M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,589 | $962K | |
| 2019 | 31,849 | $1.11M | |
| 2020 | 29,152 | $1.07M | |
| 2021 | 43,305 | $1.47M | |
| 2022 | 32,812 | $1.33M | |
| 2023 | 29,243 | $1.45M | |
| 2024incomplete | 21,699 | $1.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 6,795 | 5,455 | $1.12M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 11% | 5,784 | 1,067 | $938K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 23,994 | 18,415 | $924K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 5,266 | 4,173 | $772K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.1% | 15,905 | 10,169 | $692K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 4,387 | 3,170 | $578K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 5.8% | 6,995 | 3,452 | $500K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.8% | 1,132 | 923 | $497K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.8% | 5,673 | 5,041 | $413K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 2,150 | 1,802 | $297K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 810 | 692 | $213K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.8% | 3,228 | 2,280 | $156K |
150 more codes
| 97597 | 1.6% | 1,721 | $139K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 638 | $111K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 274 | $82K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,124 | $76K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,606 | $73K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,136 | $66K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,088 | $50K |
| 96127 | <1% | 6,145 | $49K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,872 | $39K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,738 | $38K |
| 80053 | Comprehensive metabolic panel | <1% | 4,542 | $37K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 190 | $35K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 407 | $32K |
| 73630 | <1% | 793 | $30K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,393 | $30K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,601 | $30K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 470 | $29K |
| 85610 | <1% | 4,356 | $28K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,452 | $25K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,323 | $24K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 355 | $23K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,007 | $22K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 315 | $20K |
| 85027 | <1% | 5,011 | $19K | |
| 80061 | Lipid panel | <1% | 1,776 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 441 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,494 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,395 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 495 | $15K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 216 | $14K |
| 81025 | <1% | 1,777 | $14K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 468 | $14K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 68 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,566 | $12K |
| 90686 | <1% | 988 | $11K | |
| 81001 | <1% | 3,633 | $11K | |
| 92551 | <1% | 402 | $10K | |
| 84484 | <1% | 2,182 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 889 | $8K |
| 83605 | <1% | 1,660 | $8K | |
| 83735 | <1% | 2,288 | $8K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,102 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 287 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,006 | $7K |
| 82248 | <1% | 2,858 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,552 | $6K |
| 83690 | <1% | 1,362 | $5K | |
| 80076 | <1% | 590 | $5K | |
| 86140 | <1% | 1,650 | $5K | |
| 36592 | <1% | 1,453 | $5K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 296 | $5K |
| 73562 | <1% | 102 | $4K | |
| 87070 | <1% | 677 | $4K | |
| 87077 | <1% | 766 | $4K | |
| 0011A | <1% | 113 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 73 | $4K |
| 0012A | <1% | 98 | $4K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 47 | $4K |
| 87186 | <1% | 717 | $3K | |
| 87081 | <1% | 268 | $3K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 208 | $3K |
| 99173 | <1% | 184 | $3K | |
| 81003 | <1% | 939 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,575 | $2K |
| 83880 | <1% | 198 | $2K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 47 | $2K |
| 80306 | <1% | 213 | $2K | |
| 36416 | <1% | 1,781 | $2K | |
| 82565 | <1% | 641 | $2K | |
| 87480 | <1% | 75 | $2K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 40 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 23 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 44 | $2K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 84 | $2K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 15 | $2K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14 | $2K |
| 90670 | <1% | 55 | $2K | |
| 82947 | <1% | 651 | $2K | |
| 82077 | <1% | 194 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 36 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 90 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 156 | $2K |
| 87088 | <1% | 244 | $2K | |
| 85018 | <1% | 588 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 23 | $1K |
| 73030 | <1% | 33 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 42 | $1K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 30 | $1K |
| 0064A | <1% | 61 | $1K | |
| 87660 | <1% | 75 | $1K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 14 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $991.40 |
| 87040 | <1% | 257 | $910.86 | |
| 87510 | <1% | 75 | $787.36 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 48 | $739.87 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 399 | $713.00 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 62 | $689.91 |
| 90715 | <1% | 14 | $679.30 | |
| 84460 | <1% | 235 | $664.18 | |
| 84145 | <1% | 61 | $620.22 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 31 | $599.60 |
| 90647 | <1% | 12 | $555.69 | |
| 87205 | <1% | 318 | $549.74 | |
| 88142 | <1% | 27 | $533.61 | |
| 86803 | <1% | 42 | $501.50 | |
| 87210 | <1% | 94 | $470.50 | |
| 82570 | <1% | 129 | $438.42 | |
| 99310 | Prolong nursin fac eval 15m | <1% | 35 | $419.15 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $398.86 |
| 85379 | <1% | 59 | $357.68 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 754 | $285.99 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,641 | $278.08 |
| 84466 | <1% | 26 | $263.60 | |
| 86850 | <1% | 29 | $231.46 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 140 | $221.47 |
| 87075 | <1% | 87 | $220.56 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13 | $219.45 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,897 | $189.32 |
| 84132 | <1% | 28 | $161.77 | |
| G0008 | Administration of influenza virus vaccine | <1% | 237 | $161.35 |
| 83540 | <1% | 27 | $156.49 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 891 | $129.58 |
| 85652 | <1% | 72 | $115.78 | |
| 86780 | <1% | 14 | $111.30 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 854 | $102.94 |
| 99334 | <1% | 24 | $93.86 | |
| 86901 | <1% | 43 | $93.12 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 970 | $81.65 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,023 | $76.74 |
| 80050 | General health panel | <1% | 15 | $68.90 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 480 | $63.25 |
| 85730 | <1% | 42 | $62.10 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 24 | $61.80 |
| 86900 | <1% | 29 | $55.32 | |
| 82043 | <1% | 12 | $41.79 | |
| 84450 | <1% | 14 | $31.93 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,577 | $14.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 84 | $12.28 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 72 | $12.12 |
| A9270 | Non-covered item or service | <1% | 3,832 | $3.22 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 101 | $0.45 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 311 | $0.41 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,217 | $0.02 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 78 | $0.00 |
| 0352U | 0% | 30 | $0.00 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 0% | 34 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 43 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 15 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 121 | $0.00 |
| 99354 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUDQUIST, DEBRA (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Amery Regional Medical Center, INC. | Luck, WI | $27K |
| Amery Regional Medical Center, INC | Turtle Lake, WI | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.